Hypomethylation of the Gene Is a New Potential Biomarker of Primary Osteoporosis in Men and Women.

The search for the molecular markers of osteoporosis (OP), based on the analysis of differential deoxyribonucleic acid (DNA) methylation in bone cells and peripheral blood cells, is promising for developments in the field of the early diagnosis and targeted therapy of the disease. The Runt-related transcription factor 2 () gene is one of the key genes of bone metabolism, which is of interest in the search for epigenetic signatures and aberrations associated with the risk of developing OP. Based on pyrosequencing, the analysis of the methylation profile from a pool of peripheral blood cells in men and women over 50 years of age of Russian ethnicity from the Volga-Ural region of Russia was carried out. The level of DNA methylation in three CpG sites of the gene was assessed and statistically significant hypomethylation was revealed in all three studied CpG sites in men (U = 746.5, = 0.004; U = 784, = 0.01; U = 788.5, = 0.01, respectively) and in one CpG site in women (U = 537, = 0.03) with primary OP compared with control. In the general sample, associations were preserved for the first CpG site (U = 2561, = 0.0001766). The results were obtained for the first time and indicate the existence of potentially new epigenetic signatures of in individuals with OP.